Miller et al. reported that the accuracy of p53 signature classifier genes in predicting the mutation status in human breast cancer was about 85%, which is statistically significant, but that 20 out of 251 tumors were consistently misclassified by different methods [20], suggesting that other genes affect the p53 pathway. This evidence concerns the gene TP53 and breast carcinoma.